21 October 2026 ASX Announcement ® New Product Launch: Nasodine Sinus Rinse Firebrick Pharma Limited (ASX: FRE) (the Company or Firebrick) is pleased to announce ® the launch of its third product in the Nasodine range: Nasodine Sinus Rinse. The product recently completed production and commercial...
New Product - Nasodine Sinus Rinse
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Firebrick Pharma Limited has announced the launch of its new product, Nasodine® Sinus Rinse, which is now available for healthcare professionals in Singapore. This product is an antiseptic nasal and sinus wash kit that utilizes povidone-iodine for its germ-killing properties. The announcement highlights the product's intended clinical uses and its role in the company's expanding portfolio of Nasodine products. The launch aims to provide comprehensive care for managing upper respiratory tract infections.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Change in substantial holding - Pharma Nutria
- Cleansing Notice
- Application for quotation of securities - FRE
- Nasodine Nasal Spray Approved in the Philippines
- Notice of AGM & Proxy Form & Letter to Shareholders
Later from Firebrick Pharma
- September 2026 Quarterly Activity Report & Appendix 4C
- Results of Annual General Meeting
- Proposed issue of securities - FRE
- Change of Director's Interest Notice - Al Moghaddam
- Change of Director's Interest Notice - Peter Molloy
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma